65 Hayden Avenue
Lexington, MA 02421
United States
617 674 9000
https://kaleido.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 76
Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
---|---|---|---|---|
Ms. Kimberly Hocknell | Senior Vice President of Technical Operations | N/D | N/D | N/D |
Dr. Mark A. Wingertzahn Ph.D. | Senior VP of R&D and Head of Development | N/D | N/D | 1971 |
Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the treatment of multi drug resistant infection, chronic kidney disease, atherosclerotic cardiovascular disease, cardio-metabolic syndrome, immuno-oncology, and inflammatory bowel diseases. The company has collaboration agreements with Institute Gustave Roussy, Washington University, and Janssen. Kaleido Biosciences, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
La calificación ISS Governance QuickScore de Kaleido Biosciences, Inc. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.